Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Clopidogrel

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262650

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: High dose of telmisartan
Drug: Low dose of telmisartan
Drug: HCTZ

First Posted Date: 2014-10-13

Last Posted Date: 2023-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02262780

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 277 capsule
Drug: BIBR 277 tablet

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262585

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Telmisartan/HCTZ fixed combination
Drug: Hydrochlorthiazide (HCTZ)

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02262624

Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: MicardisPlus®

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 266

Registration Number: NCT02262611

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole ER tablets
Drug: Pramipexole IR tablets
Drug: Placebo matching Pramipexole IR tablets
Drug: Placebo matching Pramipexole ER tablets
Other: Standard high-fat breakfast

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT02261103

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole immediate release (IR) tablets

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02261090

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/Amlodipine low dose
Drug: Telmisartan/Amlodipine high dose
Other: Japanese meal

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02261064

Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Hyoscine butylbromide

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02261077

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Candesartan
Drug: Placebo
Drug: Telmisartan

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02261116

AI-Powered Research

Premium Access

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers